Click here - to use the wp menu builder

Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

February 3, 2021

Newsletters Hospital News

NEW YORK–(BUSINESS WIRE)–BMS & The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Source Read More

Recent Articles